• LAST PRICE
    12.3500
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    12.3600/ 10
  • Ask / Lots
    12.9000/ 1
  • Open / Previous Close
    0.0000 / 12.3500
  • Day Range
    ---
  • 52 Week Range
    Low 5.9000
    High 13.1400
  • Volume
    1,100
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 12.22
TimeVolumeIMTX
09:32 ET363912.185
09:33 ET221712.2
09:35 ET235012.25
09:37 ET520012.24
09:39 ET10012.31
09:42 ET460712.46
09:44 ET20012.46
09:46 ET121112.465
09:48 ET165312.42
09:50 ET10012.38
09:51 ET10012.38
09:53 ET10012.385
09:55 ET100012.32
09:57 ET1186512.46
10:00 ET70012.465
10:02 ET140012.43
10:06 ET40012.48
10:08 ET89812.44
10:11 ET40012.375
10:15 ET37612.37
10:18 ET50012.335
10:22 ET195012.345
10:24 ET10012.345
10:27 ET20012.34
10:29 ET185012.36
10:33 ET30012.34
10:38 ET50012.33
10:40 ET40012.285
10:42 ET50012.25
10:44 ET161512.33
10:45 ET563912.32
10:47 ET70012.33
10:49 ET123312.33
10:54 ET10012.33
10:58 ET10012.27
11:00 ET10012.27
11:03 ET40012.28
11:07 ET20012.27
11:09 ET10012.27
11:12 ET30012.3
11:14 ET58312.335
11:16 ET219712.37
11:18 ET10012.36
11:23 ET20012.38
11:25 ET1023412.46
11:27 ET10012.48
11:30 ET281712.55
11:32 ET10012.55
11:34 ET10012.535
11:36 ET1502712.5
11:38 ET155912.51
11:41 ET10012.5
11:43 ET30612.495
11:48 ET44412.47
11:50 ET10012.475
11:52 ET10012.475
11:54 ET594812.41
11:56 ET27512.42
12:01 ET20012.415
12:06 ET30012.4
12:08 ET30012.39
12:10 ET75312.41
12:12 ET60012.385
12:15 ET20012.41
12:17 ET54112.4
12:21 ET10012.38
12:24 ET30012.39
12:26 ET148012.382
12:28 ET40012.36
12:35 ET10012.35
12:37 ET75012.33
12:39 ET20012.335
12:42 ET20012.35
12:46 ET128912.28
12:48 ET70112.3
12:50 ET20012.32
12:51 ET537312.3
12:53 ET160012.2785
12:55 ET406912.28
12:57 ET12012.28
01:00 ET15012.28
01:02 ET10012.285
01:06 ET20012.2985
01:08 ET50012.285
01:09 ET70512.27
01:11 ET368612.3
01:13 ET10012.3
01:15 ET40012.3
01:20 ET20012.3
01:22 ET20012.28
01:24 ET24112.29
01:26 ET20012.275
01:29 ET187412.26
01:33 ET30012.26
01:38 ET20012.26
01:40 ET60012.27
01:44 ET97712.28
01:47 ET84812.285
01:49 ET30012.29
01:51 ET97212.28
01:56 ET30012.28
02:00 ET123812.29
02:02 ET80012.31
02:07 ET127612.33
02:09 ET50012.32
02:12 ET10012.33
02:16 ET90012.3
02:20 ET60012.31
02:21 ET60012.34
02:23 ET50012.38
02:25 ET30012.38
02:27 ET50012.3675
02:30 ET30012.35
02:32 ET10012.36
02:36 ET109812.36
02:38 ET100312.31
02:39 ET40012.28
02:41 ET20012.29
02:43 ET202012.319
02:45 ET10012.31
02:50 ET153912.33
02:52 ET50012.3
02:54 ET77812.29
02:56 ET30012.28
02:57 ET114512.3
02:59 ET145612.29
03:01 ET40012.29
03:03 ET30012.27
03:06 ET10012.25
03:08 ET52612.26
03:10 ET190412.28
03:12 ET20012.28
03:14 ET10012.29
03:17 ET93912.285
03:19 ET52912.26
03:21 ET10012.27
03:24 ET50012.28
03:26 ET165212.27
03:28 ET10012.27
03:30 ET10012.265
03:32 ET30012.27
03:33 ET259212.26
03:35 ET137012.28
03:37 ET147412.29
03:39 ET153112.28
03:42 ET40012.28
03:44 ET60012.29
03:46 ET434712.29
03:48 ET40012.285
03:50 ET120012.3
03:51 ET310512.305
03:53 ET282712.325
03:55 ET215712.305
03:57 ET289112.31
04:00 ET1139712.35
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesIMTX
Immatics NV
1.3B
-10.6x
---
United StatesKNSA
Kiniksa Pharmaceuticals Ltd
1.4B
-199.0x
---
United StatesDCPH
Deciphera Pharmaceuticals Inc
1.3B
-7.2x
---
United StatesARCT
Arcturus Therapeutics Holdings Inc
1.1B
12.4x
---
United StatesCPRX
Catalyst Pharmaceuticals Inc
1.7B
27.0x
---
United StatesXNCR
Xencor Inc
1.6B
-13.0x
---
As of 2024-02-27

Company Information

Immatics NV is a clinical-stage biopharmaceutical company that is based in the Netherlands. The Company is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The Company develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.

Contact Information

Headquarters
Paul Ehrlich-Strasse 15TUEBINGEN, Germany 72076
Phone
---
Fax
---

Executives

Non-Executive Chairman of the Board
Peter Chambre
Chief Executive Officer, Executive Director
Harpreet Singh
Chief Financial Officer
Arnd Christ
Chief Technology Officer
Steffen Walter
Chief Medical Officer
Cedrik Britten

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$1.3B
Revenue (TTM)
$82.1M
Shares Outstanding
103.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.69
EPS
$-1.16
Book Value
$3.02
P/E Ratio
-10.6x
Price/Sales (TTM)
15.5
Price/Cash Flow (TTM)
---
Operating Margin
-97.68%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.